Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(75.0%)

N/A

2(25.0%)

8Total

Phase 2(6)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04779996Unknown

Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment

Role: lead

NCT04773769Not ApplicableUnknown

Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas

Role: lead

NCT04355247Phase 2Unknown

Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm

Role: lead

NCT01307592Phase 2Unknown

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Role: lead

NCT01016990Phase 2Unknown

Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

Role: lead

NCT01641406Phase 2Unknown

"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"

Role: lead

NCT01038258Not ApplicableUnknown

Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy

Role: lead

NCT01538641Phase 2Completed

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Role: lead

NCT00830544Phase 2Unknown

Study of Neoadjuvant Chemotherapy of Breast Cancer

Role: lead

All 9 trials loaded